Chris Hoyt

Upskill, Inc. develops enterprise software for smart glasses. The firm serves to aerospace, field services, inspection and audit, manufacturing, retail and grocery industries. The company was founded by Brian Ballard, Jeff Jenkins, Chris Hoyt and Alexander Watson in 2010 and is headquartered in Herndon, VA.

Moonshots Capital Management Co LLC (Moonshots Capital) is a venture capital firm founded by Kelly Perdew and Craig Cummings in September 2014. The firm is headquartered in Austin, Texas.

Upskill, Inc. develops enterprise software for smart glasses. The firm serves to aerospace, field services, inspection and audit, manufacturing, retail and grocery industries. The company was founded by Brian Ballard, Jeff Jenkins, Chris Hoyt and Alexander Watson in 2010 and is headquartered in Herndon, VA.

KeifeRx LLC is a clinical-stage biopharmaceutical company that develops novel and optimized tyrosine kinase inhibitors (TKIs) for the treatment of neurodegenerative and immune diseases. KeifeRx is based in McLean, VA, and was founded in 2019 by Charbel Moussa and Fernando Pagan. The company's clinical pipeline is led by Nilotinib BE, an optimized, lower dose formulation of Nilotinib, which is currently in a multicenter phase 3 clinical trial for early Alzheimer's disease. KeifeRx's TKI portfolio includes an optimized oral dose of Bosutinib and Gutinib, which are undergoing clinical trials in Lewy body dementia and optimizing and IND enabling studies, respectively. The company's technologies are designed to treat neurodegenerative diseases and an array of inflammatory diseases where there are significant unmet clinical needs and limited therapeutic options. Chris Hoyt has been the CEO of the company since 2021.

KeifeRx LLC is a clinical-stage biopharmaceutical company that develops novel and optimized tyrosine kinase inhibitors (TKIs) for the treatment of neurodegenerative and immune diseases. KeifeRx is based in McLean, VA, and was founded in 2019 by Charbel Moussa and Fernando Pagan. The company's clinical pipeline is led by Nilotinib BE, an optimized, lower dose formulation of Nilotinib, which is currently in a multicenter phase 3 clinical trial for early Alzheimer's disease. KeifeRx's TKI portfolio includes an optimized oral dose of Bosutinib and Gutinib, which are undergoing clinical trials in Lewy body dementia and optimizing and IND enabling studies, respectively. The company's technologies are designed to treat neurodegenerative diseases and an array of inflammatory diseases where there are significant unmet clinical needs and limited therapeutic options. Chris Hoyt has been the CEO of the company since 2021.

Yet Analytics, Inc. provides software solutions. It has contributed to the Advanced Distributed Learning Initiative's (ADL) Design Cohorts and the xAPI Working Groups to develop the data interoperability specification. The company was founded by Shelly Blake-Plock, Margareth Roth and Rose burt in November 2014 and is headquartered in Baltimore, MD.

Yet Analytics, Inc. provides software solutions. It has contributed to the Advanced Distributed Learning Initiative's (ADL) Design Cohorts and the xAPI Working Groups to develop the data interoperability specification. The company was founded by Shelly Blake-Plock, Margareth Roth and Rose burt in November 2014 and is headquartered in Baltimore, MD.

KeifeRx LLC is a clinical-stage biopharmaceutical company that develops novel and optimized tyrosine kinase inhibitors (TKIs) for the treatment of neurodegenerative and immune diseases. KeifeRx is based in McLean, VA, and was founded in 2019 by Charbel Moussa and Fernando Pagan. The company's clinical pipeline is led by Nilotinib BE, an optimized, lower dose formulation of Nilotinib, which is currently in a multicenter phase 3 clinical trial for early Alzheimer's disease. KeifeRx's TKI portfolio includes an optimized oral dose of Bosutinib and Gutinib, which are undergoing clinical trials in Lewy body dementia and optimizing and IND enabling studies, respectively. The company's technologies are designed to treat neurodegenerative diseases and an array of inflammatory diseases where there are significant unmet clinical needs and limited therapeutic options. Chris Hoyt has been the CEO of the company since 2021.

Moonshots Capital Management Co LLC (Moonshots Capital) is a venture capital firm founded by Kelly Perdew and Craig Cummings in September 2014. The firm is headquartered in Austin, Texas.